KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Gross Margin: 2009-2025

Historic Gross Margin for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to 42.84%.

  • Neogenomics' Gross Margin fell 178.00% to 42.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 43.46%, marking a year-over-year decrease of 8.00%. This contributed to the annual value of 43.92% for FY2024, which is 257.00% up from last year.
  • As of Q3 2025, Neogenomics' Gross Margin stood at 42.84%, which was up 0.54% from 42.61% recorded in Q2 2025.
  • Neogenomics' 5-year Gross Margin high stood at 44.92% for Q4 2024, and its period low was 32.63% during Q1 2022.
  • For the 3-year period, Neogenomics' Gross Margin averaged around 42.70%, with its median value being 42.84% (2025).
  • Over the last 5 years, Neogenomics' Gross Margin had its largest YoY gain of 1,133bps in 2021, and its largest YoY loss of 960bps in 2021.
  • Over the past 5 years, Neogenomics' Gross Margin (Quarterly) stood at 35.99% in 2021, then soared by 497bps to 40.97% in 2022, then spiked by 248bps to 43.45% in 2023, then surged by 147bps to 44.92% in 2024, then tumbled by 178bps to 42.84% in 2025.
  • Its Gross Margin was 42.84% in Q3 2025, compared to 42.61% in Q2 2025 and 43.59% in Q1 2025.